NCT01869881View on ClinicalTrials.gov

Effect of Sarpogrelate On the Nephropathy in Type 2 Diabetes (SONATA Study)

PHASE4CompletedINTERVENTIONAL
Enrollment

151

Participants

Timeline

Start Date

February 1, 2013

Primary Completion Date

November 17, 2014

Study Completion Date

January 28, 2015

Conditions
Diabetic Nephropathy
Interventions
DRUG

Anplag(Sarpogrelate)

Sarpogrelate 100mg 2 tablets, bid, 400mg/day

DRUG

Placebo

Placebo 100mg 2 tablets, bid, 400mg/day

Trial Locations (1)

Unknown

Korea University, Anam, Seoul

All Listed Sponsors
lead

Yuhan Corporation

INDUSTRY

NCT01869881 - Effect of Sarpogrelate On the Nephropathy in Type 2 Diabetes (SONATA Study) | Biotech Hunter | Biotech Hunter